5
Participants
Start Date
November 30, 2009
Primary Completion Date
October 31, 2010
Study Completion Date
June 30, 2012
AC480
Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham
Collaborators (1)
Ambit Biosciences Corporation
INDUSTRY
Annick Desjardins
OTHER